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Irisin Lowers Blood Pressure by Improvement of Endothelial
Dysfunction via AMPK-Akt-eNOS-NO Pathway in the Spontaneously
Hypertensive Rat
Jinjuan Fu, MD;* Yu Han, BS;* Jialiang Wang, MS; Yukai Liu, MD; Shuo Zheng, BS; Lin Zhou, MD, PhD; Pedro A. Jose, MD, PhD;
Chunyu Zeng, MD, PhD
Background-—Exercise is a major nonpharmacological treatment for hypertension, but its underlying mechanisms are still not
completely elucidated. Irisin, a polypeptide containing 112 amino acids, which is secreted mainly by skeletal muscle cells during
exercise, exerts a protective role in metabolic diseases, such as diabetes mellitus and obesity. Because of the close relationship
between irisin and metabolic diseases, we hypothesized that irisin may play a role in the regulation of blood pressure.
Methods and Results-—Blood pressures of male Wistar-Kyoto (WKY) rats and spontaneously hypertensive rats (SHRs) were
monitored through the carotid artery. Our study found that acute intravenous injection of irisin reduced blood pressure in SHRs, but
not WKY rats. Irisin, by itself, had no direct vasorelaxing effect in phenylephrine-preconstricted mesenteric arteries from SHRs.
However, irisin augmented the acetylcholine-induced vasorelaxation in mesenteric arteries from SHRs that could be reversed by
Nx-nitro-L-arginine-methyl ester (L-NAME; 100 lmol/L), indicating a role of nitric oxide (NO) in this action. Indeed, irisin increased NO
production and phosphorylation of endothelial nirtic oxide synthase (eNOS) in endothelial cells. 50-AMP-activated protein kinase
(AMPK) was involved in the vasorelaxing effect of irisin because compound C (20 lmol/L), an AMPK inhibitor, blocked the irisin-
mediated increase in phosphorylation of eNOS and protein kinase B (Akt) in endothelial cells and vasodilation in mesenteric arteries.
Conclusions-—We conclude that acute administration of irisin lowers blood pressure of SHRs by amelioration of endothelial
dysfunction of the mesenteric artery through the AMPK-Akt-eNOS-NO signaling pathway. ( J Am Heart Assoc. 2016;5: e003433
doi: 10.1161/JAHA.116.003433)
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H ypertension is a major public health problem, affecting1 billion people worldwide.1 Exercise, as a nonphar-
macological antihypertensive therapy, is able to decrease
blood pressure even in subjects with low responsiveness to
medical treatment,2 and regular physical exercise is highly
recommended by current European and American hyperten-
sion guidelines. However, the underlying mechanisms by
which exercise decreases blood pressure have not been fully
elucidated. Previous studies have provided evidence that
endurance aerobic training has an antihypertensive effect,
which may be caused by a decrease in the activities of the
sympathetic and renin-angiotensin systems3 and enhance-
ment of baroreceptor sensitivity.4 Additionally, Joham et al
have found that aerobic training increases insulin sensitivity.5
Sun et al proposed that moderate levels of exercise enhance
vascular endothelial nitric oxide synthase (eNOS) activity
resulting in the improvement of endothelium-dependent
vasodilatation.6 Furthermore, a recent study showed that
exercise training could even modulate specific miRNAs in the
heart, artery, and skeletal muscle to reduce blood pressure.7
The skeletal muscle is the largest endocrine organ that can
secrete interleukins, tumor necrosis factor a, leptin, and
resistin, and many diseases are closely related to its disorder.8
It has been reported that more than 1000 genes are “activated”
by exercise training in human skeletal muscle, all of which may
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contribute to improvement in health.9,10 Recently, a newly
found exercise-mediated polypeptide called irisin, the cleavage
of extra cellular domain of fibronectin type III domain-contain-
ing 5 protein (FNDC5), has drawn a lot of attention.11 Exercise
can upregulate transcription factor PPARc coactivating factor
1a, which promotes muscle-derived FNDC5 expression and
then releases irisin into the circulation to increase body energy
expenditure.12–14 Both FNDC5 and irisin are decreased in
patients with type 2 diabetes mellitus (T2DM), and irisin has
been reported to be beneficial in glucose homeostasis, insulin
resistance, and related morbidities, including obesity.15
Because of the close relationship between metabolic diseases
and hypertension, it is possible that exercise, through the
myogenic factor, irisin,16 may lower blood pressure.
Zhang et al and Jiang et al have reported that irisin
(0.1–100 lmol/L) caused endothelium-dependent and --
independent vasodilationof arteries preconstrictedwith phenyle-
phrine in mice and rats.17,18 Zhang et al also reported that bolus
injections (2 minutes) of high doses of irisin (0.625–4 lg)
decreased the blood pressure of Sprague-Dawley and sponta-
neously hypertensive rats (SHRs).17 In humans, the circulating
concentration of irisin is 3.6 ng/mL in sedentary individuals and
increases to 4.3 ng/mL in individuals undergoing aerobic
interval training.11 The circulating concentration of irisin in rats
detected by ELISA is around 300 to 600 ng/mL.19–21 Therefore,
in the present study,we studied the effect of lowdoses of irisin on
blood pressure and low concentrations of irisin on arterial
relaxation in normotensive Wistar-Kyoto (WKY) and SHRs.
Mammalian AMP-activated protein kinase (AMPK) is a
serine/threonine protein kinase that has been proposed to
function as an intracellular energy sensor and is involved in
the regulation of cellular and whole-body metabolism.22 Nitric
oxide (NO) is one of the most important factors for the
relaxation of blood vessels and changes in NO bioavailability
affect blood flow and arterial blood pressure. In the vascu-
lature, activation of endothelial AMPK has been shown to
phosphorylate eNOS1177, stimulating NO release and subse-
quent vasodilatation of both large conduit and resistance
arteries.23 The endothelium-dependent mesenteric arterial
relaxation in mice attributed to high concentrations
(0.1–100 lmol/L) of irisin has also been reported to be related
to the NO-cGMP pathway. Therefore, our present study was
designed to determine whether the AMPK-eNOS-NO pathway is
involved in the vasorelaxing effect of irisin in SHRs.
Material and Methods
Blood Pressure Measurement
Male WKY and SHRs (SLRC Laboratory Animals, Shanghai,
China), ranging in age from 16 to 18 weeks, were fed a
regular and normal sodium (1% NaCl) rat chow. To empty the
stomach and prevent food reflux into the respiratory tract
under general anesthesia, food, but not water, was withheld
12 hours before the study. Before the performance of the
experiments, rats were anesthetized with pentobarbital
(50 mg/kg body weight, intraperitoneally), placed on a heated
table to maintain rectal temperature between 36° and 37°,
and tracheotomized (PE-240). Catheters (PE-50) were placed
into both external jugular veins, which were used for
maintaining anesthesia and irisin injection. Anesthesia was
maintained by the infusion of pentobarbital sodium at
0.8 mg/100 g body weight per hour.24 Catheters (PE-50)
were also placed inside the carotid artery for monitoring
systemic arterial pressure (Cardiomax II; Columbus Instru-
ments, Columbus, OH). After achieving stable hemodynamic
conditions and recording of baseline blood pressures for
5 minutes, rats received an intravenous injection of irisin (0.1,
1, or 10 lg/kg, bolus injection) or heat-denatured irisin. To
determine the role of eNOS on the hypotensive effect of
irisin, rats were pretreated with a bolus injection of the
eNOS inhibitor, Nx-nitro-L-arginine-methyl ester (L-NAME;
30 mg/kg),25 and stable baseline blood pressure and heart
rate were recorded for 10 minutes.26 Following the bolus
injection of L-NAME, rats received either the vehicle (1%
DMSO in 0.9% NaCl) or an identical series of irisin injections
as above; blood pressure and heart rate were recorded for
60 minutes. All studies were approved by the Daping Hospital
Animal Care and Use Committee.
Preparation and Study of Small Resistance
Arteries
Vascular reactivity was determined as previously described.27
Briefly, the third-order branches of the mesenteric arteries
were dissected and cut in segments of 2 mm in length and
mounted on 40-lm stainless-steel wires in an isometric
Mulvany-Halpern small-vessel myograph (model 91 M610; J.P.
Trading, Aarhus, Denmark). Rings were maintained in phys-
iological saline solution (PSS) at 37°C and continuously
bubbled with oxygen (95%) and carbon dioxide (5%; Carbo-
gen). After a 15-minute equilibration period in oxygenated PSS
at 37°C and pH 7.4, arterial segments were stretched to the
optimal luminal diameter for active tension development.
Then, vessels were rinsed 3 times with fresh PSS and allowed
to recover to baseline for 30 minutes. In the first set of
experiments, rings were contracted with phenylephrine HCl
(PHE; 10 lmol/L) and high-potassium PSS (125 mmol/L).
To study acetylcholine (Ach)-induced endothelium-
dependent relaxation, mesenteric arterial segments were
rinsed with PSS for 30 minutes and then a cumulative
concentration-response curve to Ach (1 nmol/L to
100 mmol/L) was obtained in PHE-preconstricted segments
preincubated in the absence or presence of irisin (600 ng/mL
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[48 nmol/L] or 3000 ng/mL [240 nmol/L], 1 hour) and the
procedure was repeated with PSS containing sodium nitro-
prusside (SNP; 1–1000 nmol/L). To study the effect of irisin
on vasoconstriction, a cumulative concentration response to
PHE (1 nmol/L to 10 lmol/L) was obtained in arterial
segments preincubated in the absence or presence of irisin
(3000 ng/mL, 1 hour). The possible role of NO in Ach-
mediated vasodilation was investigated in irisin-treated and -
untreated arterial segments by preincubation with L-NAME
(100 lmol/L, 30 minutes) before studying concentration
response to ACh. In addition, the participation of cyclo-
oxygenase (COX)-mediated vasorelaxation was investigated in
irisin-treated and -untreated segments. Arteries were prein-
cubated with the nonspecific COX inhibitor indomethacin
(10 lmol/L) before performing concentration-response stud-
ies to Ach. In addition, the role of endothelium-derived
hyperpolarizing factor (EDHF) in the Ach-induced relaxation
was analyzed. For this purpose, the vasodilator response to Ach
in segments precontractedwith high K+ solution (60 mmol/L of
KCl) was studied.28 In some experiments, the role of AMPK
in Ach-induced relaxation was investigated in irisin-treated
and -untreated segments by preincubation with the AMPK
inhibitor, compound C (CC; 20 lmol/L)29 for 30 minutes
before studying the concentration response to ACh.
Cell Culture and Sample Preparation
Human coronary artery endothelial cells (Pricells, Wuhan,
China) were cultured in primary endothelial cell basal medium
(Pricells), supplemented with 10% FBS (Gibco, Grand Island,
NY), in a humidified incubator at 37°C with 95% air/5% CO2.
Before performing experiments, cells were serum starved
overnight with reagents at the indicated times and concen-
trations and then incubated at the indicated times and
concentrations. Cells (80% confluence) were flash frozen with
liquid nitrogen and homogenized in ice-cold lysis buffer
(5 mL/mg of tissue) containing protease inhibitor cocktail
and phosphatase inhibitor cocktail, sonicated, kept on ice for
1 hour, and then centrifuged at 16 000g for 30 minutes.
After centrifugation of homogenates, the supernatant was
collected and then all samples were stored at 70°C until
use.
Western Blot
After boiling the homogenates in sample buffer at 95°C for
5 minutes, 100 lg of protein were separated by SDS-PAGE
(10% polyacrylamide) and then electroblotted onto nitrocellu-
lose membranes (Bio-Rad Laboratories, Hercules, CA). Blots
were blocked overnight with 5% nonfat dry milk in Tris-PBS
with Tween 20 (TBST; 0.05% Tween 20 in 10 mmol/L of
phosphate-buffered [isotonic saline]) at 4°C with constant
shaking. Blots were subsequently incubated with antibodies
against eNOS (1:800), phosphor (p)-eNOS (1:800), neural (n)
NOS (1:500), p-nNOS (1:500), AMPK (1:1000), p-AMPK
(1:1000), protein kinase B (Akt; 1:1000), p-Akt (1:1000),
and GAPDH (1:500) overnight in a cold-room at 4°C. All of the
above antibodies were purchased from Cell Signaling Tech-
nology (Danvers, MA). Membranes were then further incu-
bated with infrared-labeled donkey antirabbit IRDye 800
(1:15 000; Li-Cor Biosciences, Lincoln, NE) at room temper-
ature for 1 hour. Membranes were washed 3 times with TBST.
Bound complexes were detected using the Odyssey Infrared
Imaging System (Li-Cor Biosciences). Images were analyzed
using the Odyssey Application Software to obtain the
integrated intensities.
Evaluation of Intracellular NO Levels With
DAF-2 DA
Human coronary artery endothelial cells were seeded into
cell-culture dishes. After cells achieved 60% confluence,
supernatants were removed and then washed 3 times in 1 mL
of HEPES buffer (119 mmol/L of NaCl, 20 mmol/L of
Na-HEPES [pH 7.4], 5 mmol/L of NaHCO3, 4.7 mmol/L of
KCl, 1.3 mmol/L of CaCl2, 1.2 mmol/L of MgSO4, 1 mmol/L
of KH2PO4, 100 lmol/L of L-arginine, and 5 mmol/L of
glucose) at 37°C. Thereafter, cells were incubated with an NO-
sensitive dye, 4,5-diaminofluorescein diacetate (DAF-2 DA;
10 lmol/L) for 45 minutes in the dark at 37°C. After loading,
cells were rinsed 3 times with HEPES buffer. The concentra-
tion of NO in cells was measured using a DAF-2 DA
fluorescence assay. Some assays were performed in the
presence of L-NAME (100 lmol/L)30 throughout the exper-
imental period. Fluorescence was measured with the excita-
tion wavelength set at 495 nm and the emission wavelength
at 515 nm, using fluorescence microscopy (Olympus America,
Inc., Melville, NY). NO fluorescence was measured every
20 seconds for 10 to 15 minutes in the same area of the
endothelial surface. Basal fluorescence intensity was
recorded before each experiment.31,32
NO Assay
Endothelial cells from human coronary artery were grown on
6-well plates, and experiments were performed 24 hours after
cells reached confluence and serum starved for 3 hours, then
stimulated with irisin (3000 ng/mL, 10 minutes). Concentra-
tions of NO metabolites nitrite and nitrate in the cell-culture
supernatant were determined using an assay based on the
enzymatic conversion of nitrate to nitrite by nitrate reductase,
followed by colorimetric detection of nitrite as an azo-dye
product of the Griess reaction (R&D Systems; Minneapolis,
MN). All samples were centrifuged to remove particulates at
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16 000g for 20 minutes at 4°C.33 One hundred microliters of
each supernatant were mixed with 100 lL of the Griess
reagent for 10 minutes at 37°C, and absorbance was
recorded on a 96-well plate using Thermo Scientific Varioskan
Flash (Thermo LabSystems, Inc., Philadelphia, PA) at
540 nm.34 Total nitrite levels were determined using a
standard curve. NO production is expressed as lmol/L.
Additional Materials
PHE, Ach, SNP, L-NAME and CC, indomethacin, HEPES, and
DMSO were obtained from Sigma-Aldrich (St. Louis, MO).
Irisin polypeptide and antibody for irisin were from Phoenix
Pharmaceuticals, Inc (Burlingame, CA), and anti-FNDC5 rabbit
polyclonal antibody was from Proteintech (Wuhan, China).
Antibodies for total AMPKa1, phosphorylated AMPKa1, total
Akt, phosphorylated Akt, total eNOS, phosphorylated eNOS,
total nNOS, phosphorylated nNOS, and GAPDH were from Cell
Signaling Technology. Infrared-labeled donkey antirabbit
IRDye 800 was from Li-Cor Biosciences. DAF-2 DA was from
Calbiochem (San Diego, CA). Cell-culture dishes were from
NEST Biotechnology Co. LTD (Rahway, NJ). The Griess reagent
system was from R&D Systems.
Statistical Analyses
Data are expressed as meanSD. For assays involving arterial
rings, the number (n) refers to the number of rats, each
providing 2 to 3 rings. Relaxation in each arterial segment is
expressed as the percentage of the contraction induced by
PHE (10 lmol/L). PHE-induced contraction in each arterial
segment is expressed as the percentage of the contraction
induced by 60 mmol/L of KCl. Comparison within groups was
made by repeated-measures ANOVA (or paired t test when
only 2 groups were compared), and comparison among
groups was made by factorial ANOVA with the Holm-Sidak
test (or t test when only 2 groups were compared). A value of
P<0.05 was considered significant.
Results
Irisin Lowered Blood Pressure by Improvement of
Endothelial Dysfunction in SHRs
Irisin decreased blood pressure in a dose-dependent (0.1, 1,
and 10 lg/kg) manner in SHRs. By contrast, in WKY rats,
irisin had no effect on blood pressure (Figure 1A). Zhang et al
also did not find an effect of 1 lg (equivalent to 4 lg/kg in
a 250-g rat), but found that 2 lg (equivalent to 8 lg/kg in
a 250-g rat) of irisin slightly decreased blood pressure of
normotensive Sprague-Dawley rats.17 Zhang et al also found
that irisin decreased blood pressure in a dose-dependent
fashion in SHRs (2, 4, and 8 lg, equivalent to 8, 16, 32 lg/kg
in a 250-g rat).17 In SHRs, the bolus intravenous injection of
irisin (10 lg/kg) started to decrease blood pressure after
Figure 1. Effect of a bolus intravenous injection
of irisin on blood pressure. Irisin decreases systolic
blood pressure (SBP) in a concentration- (0.1, 1,
and 10 lg/kg) (A) and time-dependent (B) manner
in spontaneously hypertensive rats (SHRs), but not
Wistar-Kyoto (WKY) rats. Irisin does not affect the
heart rate in either WKY or SHR (C). Irisin (10 lg/
kg) and the same dose of heat-denatured irisin
were injected, as a bolus, into the femoral vein. A,
*P<0.05 versus WKY; #P<0.05 versus baseline of
SHR; n=4/group). B, HD, Heat-denatured (*P<0.05
vs baseline or other groups at the same time point;
n=6/group).
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5 minutes, reached significance after 10 minutes, with the
maximum effect noted after 20 minutes; the vasodepressor
effect of irisin was no longer evident at 90 minutes. Heat-
denatured irisin had no effect on blood pressure (Figure 1B).
Irisin, also, had no effect on heart rate (Figure 1C).
We next determined whether irisin has any vasorelaxant
effect in mesenteric arteries. Irisin (3000 ng/mL), by itself,
had no direct vasorelaxant effect in mesenteric arteries from
SHRs (Figure 2A1) and WKY rats (Figure 2A2), preconstricted
with PHE. However, it augmented Ach-mediated vasorelax-
ation in mesenteric arteries from SHRs (Figure 2B), but not
WKY rats (Figure 2E). We also found that irisin could decrease
the vasoconstriction induced by PHE in the mesenteric artery
of SHRs (Figure 2D). SNP, an exogenous NO donor, induces
endothelium-independent vasorelaxation.35 We found that
there was no additive effect of irisin on SNP-induced
vasorelaxation in mesenteric arteries from both SHRs (Fig-
ure 2C) and WKY rats (Figure 2F). Those results indicate that
Figure 2. Effect of irisin on mesenteric arterial vasodilation in spontaneously hypertensive rats (SHRs) and Wistar-Kyoto (WKY) rats. A, Irisin
(3000 ng/mL) does not vasodilate the mesenteric artery precontracted with phenylephrine (PHE; 10 lmol/L) of either SHRs (A1) or WKY rats
(A2). B and C, Preincubation of mesenteric arteries with irisin (600 or 3000 ng/mL for 1 hour) augments Ach-mediated (1–100 nmol/L), (B) but
not SNP-mediated (1 nmol/L to 10 lmol/L), (C) vasodilation in PHE-preconstricted mesenteric arterial segments from the SHR. D, Preincubation
of mesenteric arteries with irisin (3000 ng/mL for 1 hour) decreases PHE-mediated (1 nmol/L to 10 lmol/L) vasoconstriction in SHRs. E and F,
Preincubation of mesenteric arteries with irisin (3000 ng/mL for 1 hour) neither augments Ach- nor SNP-mediated vasodilation in mesenteric
arterial segments from WKY rats (n=6; *P<0.05 vs control; #P<0.05 vs irisin (600 ng/mL). Ach indicates acetylcholine; PSS, physiological saline
solution; SNP, sodium nitroprusside.
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tvascular dysfunction in SHRs can be ameliorated by irisin in
an endothelium-dependent mechanism.
Irisin-Mediated Increase in NO Production
Decreased Endothelial Dysfunction in the
Mesenteric Artery of the SHR
NO produced in Ach-induced vasodilation is from endothelial
cells, and irisin-evoked relaxation of mesenteric arteries from
mice has been reported to be partially blocked by the NOS
inhibitor, L-NAME.18 Because the irisin sequence is highly
conserved among species,36 we determined the effect of irisin
on NO production in human coronary endothelial cells. Irisin
increased NO production, measured by DAF-2 DA fluores-
cence28,32 staining, in a time- and concentration-dependent
(Figure 3A1 and 3A2) manner. L-NAME (100 lmol/L), an
NOS inhibitor, completely abrogated the irisin-induced
increase in NO production (Figure 3B1 and 3B2). To further
confirm the results, another method to measure NO metabo-
lites (ie, nitrite and nitrate) was used; consistent with results
in Figure 3B, irisin (3000 ng/mL, 10 minutes) increased NO
production, whereas pretreatment with L-NAME (100 lmol/
L) abolished the stimulatory effect of irisin on NO production
(Figure 3C). In additional studies, human coronary endothelial
cells were preincubated with irisin (3000 ng/mL) for 1 hour,
washed with HEPES buffer, and then treated with Ach
(100 nmol/L). We found that irisin (3000 ng/mL) increased
the ability of Ach (100 nmol/L) to increase NO production
after 240 seconds of incubation (Figure 3D1 and 3D2).
We, next, evaluated the effect of irisin on eNOS-ser1177
phosphorylation (p-eNOS) levels in rat mesenteric arteries
from SHRs and human coronary endothelial cells. In the
mesenteric arteries, as compared to controls, irisin (600 ng/
mL) incubation for 30 minutes significantly stimulated eNOS-
ser1177 phosphorylation26 as early as 15 minutes, peaked at
60 minutes, and then gradually decreased close to the basal
level at 240 minutes (Figure 3E). Irisin (30-minute incubation)
also increased eNOS-ser1177 phosphorylation in a concentra-
tion-dependent manner (Figure 3F). Irisin (600 ng/mL) incu-
bation also stimulated eNOS-ser1177 phosphorylation in
human coronary endothelial cells similar to the rat mesenteric
arteries, but the effect occurred later, that is, 30 minutes
(Figure 3G). Although eNOS is the isoform of NOS that is
mainly expressed in endothelial cells,37,38 we also assessed
the effects of irisin on nNOS phosphorylation in human aortic
endothelial cells, and found that, although the expression of
nNOS was weaker than eNOS, irisin, at a 600-ng/mL
concentration, also increased nNOS phosphorylation at
60 minutes (Figure 3H).
The effect of irisin on NO production is physiologically
significant, because the synergistic vasorelaxant effect of
irisin and Ach was blocked by the NOS inhibitor, L-NAME
(100 lmol/L; Figure 4A) but not by inhibitors of COX and
EDHF, indomethacin (10 lmol/L), and KCl (60 mmol/L),
respectively (Figure 4B and 4C). Moreover, the blood-
pressure–lowering effect of irisin in SHRs was almost
completely blocked by pretreatment with L-NAME (30 mg/
kg, bolus injection; Figure 4D).
Irisin Phosphorylates eNOS Through Upregulation
of AMPK and Akt Phosphorylation in Human
Coronary Endothelial Cells
To elucidate the mechanisms underlying the increase in eNOS
phosphorylation in response to irisin, AMPK and Akt, the
upstream transducers of eNOS phosphorylation, were evalu-
ated. As shown in Figure 5A through 5C, irisin increased
AMPK (Thr172) and Akt (Ser 473) phosphorylation in a
concentration- and time-dependent manner, but had no effect
on total AMPK and Akt. An additional study showed that in the
presence of CC (20 lmol/L), an AMPK inhibitor, the irisin-
mediated increase in phosphorylations of Akt and eNOS were
blocked (Figure 6A1 through 6A4). Moreover, pretreatment
with CC partially blocked the synergistic vasorelaxant effect of
irisin and Ach (Figure 6B).
Discussion
Exercise training lowers blood pressure and is a recom-
mended nonpharmacological therapy for hypertension, but
the mechanisms involved remain elusive. Studies have shown
that exercise training attenuates aortic remodeling and
improves endothelial function caused by skeletal muscle-
cell–derived factors.3,39 Since its discovery, irisin has gained
great interest as an agent to combat obesity, T2DM, and other
metabolic diseases.40–43 Irisin has been reported to promote
human umbilical vein endothelial cell (HUVEC) proliferation
and angiogenesis through the extracellular signal-related
kinase signaling pathway and partially suppress high-
glucose–induced apoptosis.44,45 Circulating irisin levels are
positively associated with endothelium-dependent vasodila-
tion in patients with newly diagnosed T2DM without clinical
angiopathy.46 Because metabolic diseases and endothelial
dysfunction are associated with hypertension, we studied the
effect of irisin in the regulation of blood pressure. We found
that bolus intravenous administration of irisin decreases blood
pressure, but had no direct vasorelaxing effect. Instead, as
shown in Figure 7, irisin ameliorates the endothelial dysfunc-
tion of the mesenteric artery of SHRs, by increasing in NO
production and activating the AMPK-Akt-eNOS pathway.
In humans, the circulating concentration irisin detected by
mass spectrometry is 3.6 ng/mL in sedentary individuals and
increases to 4.3 ng/mL in individuals undergoing aerobic
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Figure 3. Effect of irisin on NO production and eNOS phosphorylation in mesenteric arteries
from spontaneously hypertensive rats (SHRs) and human coronary endothelial cells. A, Effect of
irisin on NO production in human coronary endothelial cells. NO production was examined after
irisin or vehicle treatment of endothelial cells. Representative experiments are shown at time point
0, 240, and 480 seconds in (A1). The summary of the data and statistical analysis is shown in (A2)
(*P<0.05 vs vehicle; n=4). B, Effect of eNOS on irisin-mediated NO production in human coronary
endothelial cells. Human coronary endothelial cells were preincubated with L-NAME (100 lmol/L,
30 minutes) and then treated with irisin (3000 ng/mL). Representative experiments are shown in
(B1). The summary of the data and statistical analysis is shown in (B2) (*P<0.05 vs L-NAME-treated
group; n=4). C, Effect of irisin on NO production, determined by measurement of nitrite and nitrate
contents in the cell-culture medium of human coronary endothelial cells. Endothelial cells were
treated with irisin (3000 ng/mL, 10 minutes) in the presence or absence of an NOS inhibitor (L-
NAME, 100 lmol/L) for 30 minutes. Medium was then collected for NO metabolite nitrite and
nitrate detection (*P<0.05 vs control group; #P<0.05 vs irisin; n=4). D, Effect of irisin on Ach-
stimulated NO production in human coronary endothelial cells. Preincubation of irisin (3000 ng/
mL) for 1 hour in human coronary endothelial cells increases Ach-induced (100 nmol/L)
production of NO. Representative experiments are shown in (D1). The summary of the data and
statistical analysis is shown in (D2) (*P<0.05 vs Ach group; n=4). E and F, Effect of irisin on eNOS
phosphorylation in themesenteric artery fromSHRs.Mesenteric arteries were incubatedwith irisin
at the indicated concentrations and periods. Results are expressed as the ratio of phosphorylated
eNOSS177 to total eNOS (*P<0.05 vs control group; n=4). G and H, Effect of irisin on eNOS
phosphorylation (G) and nNOSphosphorylation (H) in human coronary endothelial cells. Endothelial
cells were incubated with irisin at the indicated concentrations and periods. Results are expressed
as the ratio of phosphorylated eNOS and nNOS to total eNOS and nNOS (*P<0.05 vs control group,
n=4). Ach indicates acetylcholine; DAF-2 DA, 4,5-diaminofluorescein diacetate; DU, density units;
eNOS, endothelial nitric oxide synthase; L-NAME, Nx-nitro-L-arginine methyl ester; nNOS, neural
nitric oxide synthase; NO, nitric oxide. RU, relative units.
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interval training.11 The circulating concentration of irisin in the
rat detected by ELISA is around 300 to 600 ng/mL.19–21
Therefore, we chose 600 ng/mL to study the effect of irisin
on the function of rat mesenteric artery.
It is well known that Ach induces vasorelaxation through
endothelium-derived relaxing factors that include NO, prosta-
cyclin (prostaglandin I2; PGI2), and EDHF.
47 Therefore, the NO
inhibitor, L-NAME, and COX inhibitor, indomethacin, were
used to determine whether or not the increase in ACh-induced
vasodilation induced by irisin is attributed to NO or
prostaglandins. The vasorelaxation induced by EDHF is
endothelium-dependent opening of K+ channels that leads
to hyperpolarization of vascular smooth muscle cells.48 In
order to determine whether or not the increase in ACh-
induced vasodilation induced by irisin is attributed to an
increase in EDHF activity, mesenteric resistance arteries were
precontracted with a high K+ solution (60 mmol/L).28 Our
results suggest that the vasodilatory synergism of irisin and
Ach can be blocked by L-NAME, indicating the involvement of
NO. After preincubation with indomethacin or 60 mmol/L of
Figure 4. Role of NO, PGI2, and EDHF on the irisin-mediated augmentation of Ach-mediated effect in the
mesenteric artery of the spontaneously hypertensive rat (SHR). A and B, Role of NO (A) or PGI2 (B) in the
augmented effect of irisin on Ach-mediated vasodilation in the mesenteric artery of the SHR. PHE-
precontracted mesenteric artery segments from SHRs were preincubated with irisin (3000 ng/mL, 1 hour)
and then incubated with different concentrations of Ach (1–100 nmol/L). The irisin-mediated augmentation
of Ach-mediated vasodilation was evaluated with or without L-NAME (100 lmol/L, 30 minutes) (A) or
indomethacin (10 lmol/L) (B). (A, n=6; *P<0.05 vs control; #P<0.05 vs irisin; B, *P<0.05 vs irisin; #P<0.05
vs indomethacin; n=6). C, Role of EDHF in the augmented effect of irisin on Ach-mediated vasodilation in
the mesenteric artery of the SHR. Mesenteric artery was precontracted with PHE in the presence or
absence of KCl (60 mmol/L) and then treated with Ach with or without preincubation with irisin (3000 ng/
mL; 1 hour; #P<0.05 vs irisin [KCl]; *P<0.05 vs control group; n=6). D, Role of eNOS on irisin-mediated
blood pressure lowering effect in the SHR. SHRs were treated with L-NAME (30 mg/kg, bolus injection) and
then irisin (10 lg/kg, bolus injection). The effect of irisin on systolic blood pressure (SBP) was monitored
(n=5; P=NS). Ach indicates acetylcholine; EDHF, endothelium-derived hyperpolarizing factor; eNOS,
endothelial nitric oxide synthase; L-NAME, Nx-nitro-L-arginine methyl ester; NO, nitric oxide; NS, not
significant. PHE, phenylephrine.
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K+ solution, ACh-induced relaxation was decreased to a
similar extent in both experimental conditions, indicating that
the synergistic vasorelaxation effect of irisin with Ach in SHR
is independent of EDHF and COX pathways. Although irisin
has been reported to dilate rat mesenteric arteries through
ATP-sensitive potassium channels, this effect was noted at
micromolar concentrations of irisin,17 much higher than the
nanomolar concentrations of circulating irisin, used in the
current report.44–46 The ability of higher concentrations of
irisin to relax mouse mesenteric arteries has also been
reported to be independent of PGI2.
18 In additional studies,
we found that irisin concentration- and time-dependently
enhanced the phosphorylation of eNOS from endothelial cells
and mesenteric arteries, an effect that was blocked by
L-NAME. Moreover, pretreatment with L-NAME to block NOS
almost completely prevented the blood-pressure–lowering
effect of irisin in SHRs. Endothelial cells express eNOS to a
greater extent than other NOS isoforms, including nNOS.37,49
Although we also found that irisin could stimulate the
phosphorylation of nNOS, its effect was weaker than eNOS.
Thus, all pieces of evidence show a role of NO, presumably
generated mainly by eNOS, in the irisin-mediated amelioration
of endothelial dysfunction and high blood pressure.
At present, various methods have been proposed to detect
NO production inside or outside living organisms. Fluorescent
dyes, like DAF-2DA, are the direct way to quantify NO
production and are still widely used,50,51 although doubts
about its specificity have recently been raised.51,52 Those
studies provide evidence that DAF-2DA dyes react not only
with NO, but also with peroxidase enzyme and hydrogen
peroxide; both are secreted in the case of elicitation of
suspension cells, with a fluorescence increase mimicking NO
release from cells. Besides, NO has an extremely short half-
life53; therefore, it is difficult to detect NO production in so
short a time. Because of the above-mentioned limitation,
scientists realize that measurement of NO metabolites (ie,
nitrite and nitrate) might be an alternative method, deter-
mined by the Griess reaction method,54 chemilumines-
cence,55 or high-performance liquid chromatography
(HPLC).56 Among these methods, HPLC, with the advantages
of high sensitivity, was widely applied recently. Because of the
lack of HPLC equipment, we used DAF-2 DA fluorescent
Figure 5. Effect of irisin on AMPK and Akt phosphorylation in human coronary endothelial cells.
Endothelial cells were incubated with irisin at the indicated concentrations and times. Phospho-AMPKa1 (A
and B) and phospho-Akt (C) results were normalized by total AMPKa1 and Akt, respectively (*P<0.05 vs
control group; n=4). Akt indicates protein kinase B; AMPK, AMP-activated protein kinase; DU, density units;
p, phospho.
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probes and the Griess reaction method to determine NO
production instead in the present study. We found that irisin
increased NO production, whereas pretreatment with L-NAME
abolished the stimulatory effect of irisin on NO production,
which is consisted with other reports; for example, Han et al
found that irisin could stimulate NO production in HUVECs.54
AMPK has been characterized as an energy sensor
(sensitive to the AMP/ATP ratio) in the regulation of glucose
uptake and fatty acid oxidation in the whole body.22,57 AMPK
is involved in endothelial cell homeostasis.58,59 The principal
AMPK catalytic subunit isoform contributing to AMPK activity
in endothelial cells is the a1 isoform.
60 Previous studies have
shown that AMPK induces phosphorylation of eNOS at serine-
1177 and activates NO generation in endothelial cells.61,62 A
recent study also found that high concentrations of AMPK
agonist also dilate resistance arteries through activation of
SERCA and BKCa channels in smooth muscle.63 Irisin
promotes the synthesis of uncoupling protein 1 (UCP1) in
brown fat cells,12 and UCP1 causes bioenergetically uncou-
pled energy dissipation (heat production, thermogenesis).64
Exercise activates AMPK in skeletal muscle and endothelial
cells.65,66 In our present study, we found that exogenous irisin
dose- and time-dependently enhances the phosphorylation of
AMPK. Inhibition of AMPK prevents the irisin-mediated
phosphorylation of eNOS and Akt. We also found that
inhibition of AMPK partially blocks the irisin-mediated
increase in Ach-induced relaxation of mesenteric artery.
Therefore, AMPK/Akt/eNOS/NO is involved in the vasodila-
tory effect of irisin.
In conclusion, we found that low doses or physiological
concentrations of irisin did not lower blood pressure or dilate
the mesenteric artery of WKY rats. By contrast, irisin
decreased blood pressure of SHRs in a concentration-
dependent manner. Physiological concentrations of irisin (48
and 240 nmol/L) did not dilate the mesenteric artery of SHRs
precontracted by PHE. However, the same concentration of
irisin ameliorated the impaired-endothelial relaxation
response to Ach in the mesenteric artery of the SHR. The
vasodilatory effect of irisin was caused by the stimulation of
arterial endothelial cells to increase AMP/ATP levels and NO
Figure 6. Role of AMPK on irisin-mediated stimulation of Akt and eNOS phosphorylation in human coronary endothelial cells and
vasorelaxation in mesenteric artery from the spontaneously hypertensive rat (SHR). A, Endothelial cells were treated with irisin (600 ng/mL,
1 hour) in the presence or absence of an AMPK inhibitor (compound C [CC], 20 lmol/L) for 30 minutes. Representative immunoblots of
phosphorylated AMPK, Akt, and eNOS are shown in (A1). The summary of the quantified blots and statistical analyses are shown in (A2 through
A4). Phospho-AMPKa1, -Akt, and -eNOS results were then normalized to GAPDH (*P<0.05 vs control group;
#P<0.05 vs irisin; n=4). B, Role of
AMPK on the irisin-mediated augmentation of Ach-induced vasodilation in mesenteric artery from the SHR. Mesenteric artery was preincubated
with irisin (3000 ng/mL, 1 hour) and then treated with Ach in the presence or absence of compound C (CC, 20 lmol/L, 30 minutes) (*P<0.05
vs irisin+ CC; #P<0.05 vs irisin; n=6). Ach indicates acetylcholine; Akt, protein kinase B; AMPK, AMP-activated protein kinase; DU, density units;
eNOS, endothelial nitric oxide synthase; p, phospho; PHE, phenylephrine.
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release by activation of AMPK and Akt. Upregulation of NO
production improved the endothelial dysfunction in the SHR
and ultimately decreased blood pressure, which may be
helpful to normalize the high blood pressure of hypertensive
patients.
Sources of Funding
These studies were supported, in part, by grants from the
National Natural Science Foundation of China (31430043,
31130029, National International Technology Special Grant
(2014DFA31070), and National Basic Research Program of
China (2013CB531104).
Disclosures
None.
References
1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global
burden of hypertension: analysis of worldwide data. Lancet. 2005;365:
217–223.
2. Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic
exercise reduces blood pressure in resistant hypertension. Hypertension.
2012;60:653–658.
3. Gu Q, Wang B, Zhang XF, Ma YP, Liu JD, Wang XZ. Contribution of renin-
angiotensin system to exercise-induced attenuation of aortic remodeling and
improvement of endothelial function in spontaneously hypertensive rats.
Cardiovasc Pathol. 2014;23:298–305.
4. Matsukawa K, Ishii K, Kadowaki A, Liang N, Ishida T. Differential effect of
central command on aortic and carotid sinus baroreceptor-heart rate reflexes
at the onset of spontaneous, fictive motor activity. Am J Physiol Heart Circ
Physiol. 2012;303:H464–H474.
5. Joham AE, Teede HJ, Hutchison SK, Stepto NK, Harrison CL, Strauss BJ, Paul E,
Watt MJ. Pigment epithelium-derived factor, insulin sensitivity, and adiposity in
polycystic ovary syndrome: impact of exercise training. Obesity (Silver Spring).
2012;20:2390–2396.
6. Sun MW, Zhong MF, Gu J, Qian FL, Gu JZ, Chen H. Effects of different levels of
exercise volume on endothelium-dependent vasodilation: roles of nitric oxide
synthase and heme oxygenase. Hypertens Res. 2008;31:805–816.
7. Neves VJ, Fernandes T, Roque FR, Soci UP, Melo SF, de Oliveira EM. Exercise
training in hypertension: role of microRNAs. World J Cardiol. 2014;6:713–727.
8. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J
Pharmacol Sci. 2014;125:125–131.
9. Pan X, Zhang Y, Tao S. Effects of Tai Chi exercise on blood pressure and
plasma levels of nitric oxide, carbon monoxide and hydrogen sulfide in real-
world patients with essential hypertension. Clin Exp Hypertens. 2015;37:8–14.
10. Venkatesh B, Lee AP, Swann JB, Ohta Y, Flajnik MF, Kasahara M, Boehm T,
Warren WC. Venkatesh et al. reply. Nature. 2014;511:E9–E10.
11. Jedrychowski MP, Wrann CD, Paulo JA, Gerber KK, Szpyt J, Robinson MM, Nair
KS, Gygi SP, Spiegelman BM. Detection and quantitation of circulating human
irisin by tandem mass spectrometry. Cell Metab. 2015;22:734–740.
12. Bostrom P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Bostrom
EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Hojlund
K, Gygi SP, Spiegelman BM. A PGC1-alpha-dependent myokine that drives
brown-fat-like development of white fat and thermogenesis. Nature.
2012;481:463–468.
13. Villarroya F. Irisin, turning up the heat. Cell Metab. 2012;15:277–278.
14. Kelly DP. Medicine. Irisin, light my fire. Science. 2012;336:42–43.
15. Sanchis-Gomar F, Lippi G, Mayero S, Perez-Quilis C, Garcia-Gimenez JL. Irisin:
a new potential hormonal target for the treatment of obesity and type 2
diabetes. J Diabetes. 2012;4:196.
16. Huh JY, Siopi A, Mougios V, Park KH, Mantzoros CS. Irisin in response to
exercise in humans with and without metabolic syndrome. J Clin Endocrinol
Metab. 2015;100:E453–E457.
17. Zhang W, Chang L, Zhang C, Zhang R, Li Z, Chai B, Li J, Chen E, Mulholland M.
Central and peripheral irisin differentially regulate blood pressure. Cardiovasc
Drugs Ther. 2015;29:121–127.
18. Jiang M, Wan F, Wang F, Wu Q. Irisin relaxes mouse mesenteric arteries
through endothelium-dependent and endothelium-independent mechanisms.
Biochem Biophys Res Commun. 2015;468:832–836.
19. Samy DM, Ismail CA, Nassra RA. Circulating irisin concentrations in rat models
of thyroid dysfunction—effect of exercise. Metabolism. 2015;64:804–813.
20. Czarkowska-Paczek B, Zendzian-Piotrowska M, Gala K, Sobol M, Paczek L. One
session of exercise or endurance training does not influence serum levels of
irisin in rats. J Physiol Pharmacol. 2014;65:449–454.
21. Seo DY, Kwak HB, Lee SR, Cho YS, Song IS, Kim N, Bang HS, Rhee BD, Ko KS,
Park BJ, Han J. Effects of aged garlic extract and endurance exercise on
skeletal muscle FNDC-5 and circulating irisin in high-fat-diet rat models. Nutr
Res Pract. 2014;8:177–182.
22. Carling D, Viollet B. Beyond energy homeostasis: the expanding role of AMP-
activated protein kinase in regulating metabolism. Cell Metab. 2015;21:799–
804.
23. Zheng Q, Yuan Y, Yi W, Lau WB, Wang Y, Wang X, Sun Y, Lopez BL, Christopher
TA, Peterson JM, Wong GW, Yu S, Yi D, Ma XL. C1q/TNF-related proteins, a
family of novel adipokines, induce vascular relaxation through the adiponectin
receptor-1/AMPK/eNOS/nitric oxide signaling pathway. Arterioscler Thromb
Vasc Biol. 2011;31:2616–2623.
24. Chen Y, Asico LD, Zheng S, Villar VA, He D, Zhou L, Zeng C, Jose PA. Gastrin
and D1 dopamine receptor interact to induce natriuresis and diuresis.
Hypertension. 2013;62:927–933.
25. Lopez RM, Perez T, Castillo C, Castillo MC, Castillo EF. Acute intravenous
injection and short-term oral administration of N(G) -nitro-L-arginine methyl
ester to the rat provoke increased pressor responses to agonists and
hypertension, but not inhibition of acetylcholine-induced hypotensive
responses. Fundam Clin Pharmacol. 2011;25:333–342.
Figure 7. Schematic illustration of the proposed
signaling mechanism involved in irisin-mediated
vasorelaxation and lowering blood pressure in the
spontaneously hypertensive rat (SHR). During exer-
cise, the skeletal muscles release irisin into the
circulation, which acts on arterial endothelial cells
to increase AMP/ATP levels and NO release by
activation of AMPK and Akt. The upregulation of NO
ameliorates endothelial dysfunction and, ultimately,
decreases blood pressure. Akt indicates protein
kinase B; AMPK, AMP-activated protein kinase; NO,
nitric oxide; p, phospho.
DOI: 10.1161/JAHA.116.003433 Journal of the American Heart Association 11
Irisin Lowers Blood Pressure in the Spontaneously Hypertensive Rat Fu et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at G
eorge W
ashington U
niversity on N
ovem
ber 1, 2016
http://jaha.ahajournals.org/
D
ow
nloaded from
 
26. Fink J, Fan NY, Rosenfeld L, Stier CT Jr. Contribution of endothelin to the acute
pressor response of L-NAME in stroke-prone spontaneously hypertensive rats.
J Cardiovasc Pharmacol. 1998;31:618–622.
27. Fu J, Han Y, Wang H, Wang Z, Liu Y, Chen X, Cai Y, Guan W, Yang D, Asico LD,
Zhou L, Jose PA, Zeng C. Impaired dopamine D1 receptor-mediated
vasorelaxation of mesenteric arteries in obese Zucker rats. Cardiovasc
Diabetol. 2014;13:50.
28. Xavier FE, Blanco-Rivero J, Sastre E, Caracuel L, Callejo M, Balfagon G.
Tranilast increases vasodilator response to acetylcholine in rat mesenteric
resistance arteries through increased EDHF participation. PLoS One. 2014;9:
e100356.
29. Pyla R, Osman I, Pichavaram P, Hansen P, Segar L. Metformin exaggerates
phenylephrine-induced AMPK phosphorylation independent of CAMKKbeta
and attenuates contractile response in endothelium-denuded rat aorta.
Biochem Pharmacol. 2014;92:266–279.
30. Kim JA, Formoso G, Li Y, Potenza MA, Marasciulo FL, Montagnani M, Quon MJ.
Epigallocatechin gallate, a green tea polyphenol, mediates NO-dependent
vasodilation using signaling pathways in vascular endothelium requiring
reactive oxygen species and Fyn. J Biol Chem. 2007;282:13736–13745.
31. Yuen CY, Wong WT, Tian XY, Wong SL, Lau CW, Yu J, Tomlinson B, Yao X,
Huang Y. Telmisartan inhibits vasoconstriction via PPARgamma-dependent
expression and activation of endothelial nitric oxide synthase. Cardiovasc Res.
2011;90:122–129.
32. Wang Y, Dong J, Liu P, Lau CW, Gao Z, Zhou D, Tang J, Ng CF, Huang Y.
Ginsenoside Rb3 attenuates oxidative stress and preserves endothelial
function in renal arteries from hypertensive rats. Br J Pharmacol.
2014;171:3171–3181.
33. Babbitt DM, Kim JS, Forrester SJ, Brown MD, Park JY. Effect of interleukin-10
and laminar shear stress on endothelial nitric oxide synthase and nitric oxide
in African American human umbilical vein endothelial cells. Ethn Dis.
2015;25:413–418.
34. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-
nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150–166.
35. Iwatani Y, Kosugi K, Isobe-Oku S, Atagi S, Kitamura Y, Kawasaki H.
Endothelium removal augments endothelium-independent vasodilatation in
rat mesenteric vascular bed. Br J Pharmacol. 2008;154:32–40.
36. Li X, Fang W, Hu Y, Wang Y, Li J. Characterization of fibronectin type III domain-
containing protein 5 (FNDC5) gene in chickens: cloning, tissue expression, and
regulation of its expression in the muscle by fasting and cold exposure. Gene.
2015;570:221–229.
37. Bachetti T, Comini L, Curello S, Bastianon D, Palmieri M, Bresciani G, Callea F,
Ferrari R. Co-expression and modulation of neuronal and endothelial nitric oxide
synthase in human endothelial cells. J Mol Cell Cardiol. 2004;37:939–945.
38. Baskova IP, Alekseeva A, Kostiuk SV, Neverova ME, Smirnova TD, Veiko NN.
Use of the most recent reagent (CUFL) for stimulation of NO synthesis by the
medicinal leech salivary cell secretion in the cultures of human endothelium
cells (HUVEC) and in rat cardiomiocytes. Biomed Khim. 2012;58:65–76.
39. Gu Q, Wang B, Zhang XF, Ma YP, Liu JD, Wang XZ. Chronic aerobic exercise
training attenuates aortic stiffening and endothelial dysfunction through
preserving aortic mitochondrial function in aged rats. Exp Gerontol.
2014;56:37–44.
40. Zhu D, Wang H, Zhang J, Zhang X, Xin C, Zhang F, Lee Y, Zhang L, Lian K, Yan
W, Ma X, Liu Y, Tao L. Irisin improves endothelial function in type 2 diabetes
through reducing oxidative/nitrative stresses. J Mol Cell Cardiol.
2015;87:138–147.
41. Chen JQ, Huang YY, Gusdon AM, Qu S. Irisin: a new molecular marker and
target in metabolic disorder. Lipids Health Dis. 2015;14:2.
42. Liu TY, Shi CX, Gao R, Sun HJ, Xiong XQ, Ding L, Chen Q, Li YH, Wang JJ, Kang
YM, Zhu GQ. Irisin inhibits hepatic gluconeogenesis and increases glycogen
synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes.
Clin Sci (Lond). 2015;129:839–850.
43. Wu J, Spiegelman BM. Irisin ERKS the fat. Diabetes. 2014;63:381–383.
44. Song H, Wu F, Zhang Y, Wang F, Jiang M, Wang Z, Zhang M, Li S, Yang L, Wang
XL, Cui T, Tang D. Irisin promotes human umbilical vein endothelial cell
proliferation through the ERK signaling pathway and partly suppresses high
glucose-induced apoptosis. PLoS One. 2014;9:e110273.
45. Wu F, Song H, Zhang Y, Mu Q, Jiang M, Wang F, Zhang W, Li L, Li H, Wang Y,
Zhang M, Li S, Yang L, Meng Y, Tang D. Irisin induces angiogenesis in human
umbilical vein endothelial cells in vitro and in zebrafish embryos in vivo via
activation of the ERK signaling pathway. PLoS One. 2015;10:e0134662.
46. Xiang L, Xiang G, Yue L, Zhang J, Zhao L. Circulating irisin levels are positively
associated with endothelium-dependent vasodilation in newly diagnosed type
2 diabetic patients without clinical angiopathy. Atherosclerosis.
2014;235:328–333.
47. Kang KT. Endothelium-derived relaxing factors of small resistance arteries in
hypertension. Toxicol Res. 2014;30:141–148.
48. Triggle CR, Samuel SM, Ravishankar S, Marei I, Arunachalam G, Ding H. The
endothelium: influencing vascular smooth muscle in many ways. Can J Physiol
Pharmacol. 2012;90:713–738.
49. Karimi Galougahi K, Liu CC, Garcia A, Gentile C, Fry NA, Hamilton EJ, Hawkins
CL, Figtree GA. b3 Adrenergic stimulation restores nitric oxide/redox balance
and enhances endothelial function in hyperglycemia. J Am Heart Assoc.
2016;5:e002824 doi: 10.1161/JAHA.115.002824.
50. Villalba N, Sonkusare SK, Longden TA, Tran TL, Sackheim AM, Nelson MT,
Wellman GC, Freeman K. Traumatic brain injury disrupts cerebrovascular tone
through endothelial inducible nitric oxide synthase expression and nitric oxide
gain of function. J Am Heart Assoc. 2014;3:e001474 doi: 10.1161/
JAHA.114.001474.
51. Cheang WS, Tian XY, Wong WT, Lau CW, Lee SS, Chen ZY, Yao X, Wang N,
Huang Y. Metformin protects endothelial function in diet-induced obese mice
by inhibition of endoplasmic reticulum stress through 50 adenosine
monophosphate-activated protein kinase-peroxisome proliferator-activated
receptor delta pathway. Arterioscler Thromb Vasc Biol. 2014;34:830–836.
52. Ruemer S, Krischke M, Fekete A, Lesch M, Mueller MJ, Kaiser WM. Methods to
detect nitric oxide in plants: are DAFs really measuring NO? Methods Mol Biol.
2016;1424:57–68.
53. Kelm M, Schrader J. Control of coronary vascular tone by nitric oxide. Circ Res.
1990;66:1561–1575.
54. Han F, Zhang S, Hou N, Wang D, Sun X. Irisin improves endothelial function in
obese mice through the AMPK-eNOS pathway. Am J Physiol Heart Circ Physiol.
2015;309:H1501–H1508.
55. MacArthur PH, Shiva S, Gladwin MT. Measurement of circulating nitrite and S-
nitrosothiols by reductive chemiluminescence. J Chromatogr B Analyt Technol
Biomed Life Sci. 2007;851:93–105.
56. Wu A, Duan T, Tang D, Xu Y, Feng L, Zheng Z, Zhu J, Wang R, Zhu Q.
Determination of nitric oxide-derived nitrite and nitrate in biological samples
by HPLC coupled to nitrite oxidation. Chromatographia. 2013;76:1649–1655.
57. Qi D, Young LH. AMPK: energy sensor and survival mechanism in the ischemic
heart. Trends Endocrinol Metab. 2015;26:422–429.
58. Fisslthaler B, Fleming I. Activation and signaling by the AMP-activated protein
kinase in endothelial cells. Circ Res. 2009;105:114–127.
59. Dagher Z, Ruderman N, Tornheim K, Ido Y. The effect of AMP-activated protein
kinase and its activator AICAR on the metabolism of human umbilical vein
endothelial cells. Biochem Biophys Res Commun. 1999;265:112–115.
60. Zou MH, Hou XY, Shi CM, Nagata D, Walsh K, Cohen RA. Modulation by
peroxynitrite of Akt- and AMP-activated kinase-dependent Ser1179 phospho-
rylation of endothelial nitric oxide synthase. J Biol Chem. 2002;277:32552–
32557.
61. Ikeda Y, Aihara K, Yoshida S, Iwase T, Tajima S, Izawa-Ishizawa Y, Kihira Y,
Ishizawa K, Tomita S, Tsuchiya K, Sata M, Akaike M, Kato S, Matsumoto T,
Tamaki T. Heparin cofactor II, a serine protease inhibitor, promotes
angiogenesis via activation of the AMP-activated protein kinase-endothelial
nitric-oxide synthase signaling pathway. J Biol Chem. 2012;287:34256–
34263.
62. Morrow VA, Foufelle F, Connell JM, Petrie JR, Gould GW, Salt IP. Direct
activation of AMP-activated protein kinase stimulates nitric-oxide synthesis in
human aortic endothelial cells. J Biol Chem. 2003;278:31629–31639.
63. Schneider H, Schubert KM, Blodow S, Kreutz CP, Erdogmus S, Wiedenmann
M, Qiu J, Fey T, Ruth P, Lubomirov LT, Pfitzer G, Mederos YSM, Hardie DG,
Gudermann T, Pohl U. AMPK dilates resistance arteries via activation of
SERCA and BKCa channels in smooth muscle. Hypertension. 2015;66:108–
116.
64. Shabalina IG, Kalinovich AV, Cannon B, Nedergaard J. Metabolically inert
perfluorinated fatty acids directly activate uncoupling protein 1 in brown-fat
mitochondria. Arch Toxicol. 2016;90:1117–1128.
65. Lee-Young RS, Ayala JE, Hunley CF, James FD, Bracy DP, Kang L, Wasserman
DH. Endothelial nitric oxide synthase is central to skeletal muscle metabolic
regulation and enzymatic signaling during exercise in vivo. Am J Physiol Regul
Integr Comp Physiol. 2010;298:R1399–R1408.
66. Huh JY, Mougios V, Kabasakalis A, Fatouros I, Siopi A, Douroudos II, Filippaios
A, Panagiotou G, Park KH, Mantzoros CS. Exercise-induced irisin secretion is
independent of age or fitness level and increased irisin may directly modulate
muscle metabolism through AMPK activation. J Clin Endocrinol Metab.
2014;99:E2154–E2161.
DOI: 10.1161/JAHA.116.003433 Journal of the American Heart Association 12
Irisin Lowers Blood Pressure in the Spontaneously Hypertensive Rat Fu et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 at G
eorge W
ashington U
niversity on N
ovem
ber 1, 2016
http://jaha.ahajournals.org/
D
ow
nloaded from
 
Zeng
Jinjuan Fu, Yu Han, Jialiang Wang, Yukai Liu, Shuo Zheng, Lin Zhou, Pedro A. Jose and Chunyu
NO Pathway in the Spontaneously Hypertensive Rat−eNOS
−Akt−Irisin Lowers Blood Pressure by Improvement of Endothelial Dysfunction via AMPK
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.116.003433
2016;5:e003433; originally published October 26, 2016;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/5/11/e003433
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 at G
eorge W
ashington U
niversity on N
ovem
ber 1, 2016
http://jaha.ahajournals.org/
D
ow
nloaded from
 
